netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
08.01 Cytotoxic drugs (2,0)
08.01.01 Alkylating drugs (4,7)
08.01.02 Anthracyclines and other cytotoxic antibiotics (1,13)
08.01.03 Antimetabolites (9,12)
08.01.04 Vinca alkaloids and etoposide (1,9)
08.01.05 Other antineoplastic drugs (34,0)
Arsenic trioxide (1,0)
Bevacizumab (1,0)
Brentuximab vedotin (1,0)
Dacarbazine and Temozolomide (1,1)
Hydroxycarbamide (1,0)
Ipilimumab (1,0)
Protein kinase inhibitors (22,3)
Taxanes (4,0)
Topoisomerase I inhibitors (2,0)
Trabectedin (1,0)
Trastuzumab (2,0)
08.02 Drugs affecting the immune response (0,0)
08.02.01 Antiproliferative immunosuppressants (2,2)
08.02.02 Corticosteroids and other immunosuppressants (5,11)
08.02.03 Anti-lymphocyte monoclonal antibodies (16,0)
08.02.04 Other immunomodulating drugs (8,2)
Interferon Alfa (3,2)
Interferon beta (1,0)
Dimethyl fumarate (1,0)
Fingolimod (1,0)
Glatiramer acetate (1,0)
Lenalidomide, pomalidomide, and thalidomide (2,0)
Mifamurtide (1,0)
Natalizumab (1,0)
08.03 Sex hormones and hormone antagonists in malignant disease (0,0)
08.03.01 Oestrogens (2,1)
08.03.02 Progestogens (0,4)
08.03.03 Androgens (0,0)
08.03.04 Hormone antagonists (0,0)
08.03.04.01 Breast cancer (5,5)
08.03.04.02 Prostate cancer and gonadorelin analogues (0,0)
Gonadorelin analogues (1,1)
Anti-androgens (10,4)
08.03.04.03 Somatostatin analogues (3,0)
netFormulary